RANDOM COURTESY Iowa — One in four women with metastatic invasive breast cancer will progress to a more seriously advanced stage that is less sensitive to treatment — a route that underscores the urgent need for immune-based clinical testing and treatment according to preliminary results published in the April issue of JAMA Oncology.
Increasing the sensitivity and specificity of NK-variant breast cancer (IC) remains an urgent public health priority says lead author Jennifer A. Fox M. D. president and Raymond R. Herrington assistant professor of biological chemistry at Iowa State University. By incorporating biomarkers into comprehensive tumor surveillance tools its possible to provide timely access to enhanced predictive performance and avenues to improve therapeutic options in women with modern contralateral erythrocytologic growths.
Fox says diagnosing treating and managing IC patients is urgent considering that it can be asymptomatic or suboptimal. For the current study she and colleagues analyzed data collected from 430 newborn IC patients between 2000 and 2015. Among these subjects 23 had metastatic invasive infarction 46 had metastatic anemia and 69 had early-stage ovarian cancer. Among both groups antibody responses correlated significantly to the median progression-free survival (PfS) an important indicator of long-term survival. The researchers also showed that multiple levels of an individuals teratogenicity known as reactivation correlated with a patients likelihood of having a relapses event.
Fox says the study also found that a patients genetic history was not predictive of backward progression which is relatively common among IC patients. These findings help provide more granular information about who would progress in a more advanced ICD.
My hope is that improved understanding of tumor biology and immune responses will lead to more personalized treatment options and improved patient outcomes Fox says.